Jennerex Appoints Hoyoung Huh to its Board of directors

Aujourd’hui, Jennerex Inc., une compagnie stage-clinique biothérapeutique, a annoncé la nomination de Hoyoung Huh, M.D., Ph.D. à son conseil d’administration.

Jennerex Inc., a clinical-stage cancer biotherapeutics company, today announced the appointment of Hoyoung Huh, M.D., Ph.D. to its board of directors. Dr. Huh is currently chairman of BiPar Sciences, Inc., an independent wholly-owned subsidiary of sanofi-aventis, and chairman of Epizyme, Inc., representing two leading novel cancer therapeutics companies.

Read more on www.streetinsider.com>
Visit Jennerex.com>

About Ottawa Technology Transfer Network
The Ottawa Technology Transfer Network (OTTN) is a collaboration among academic research institutions affiliated with the University of Ottawa and who's goal is to enhance the economic impact of research commercialization through the sharing of best practices, enhanced market knowledge, student engagement and proactive industrial interation. OTTN members include the University of Ottawa, the Ottawa Hospital Research Institutie (OHRI), the Childrens' Hospital of Eastern Ontario (CHEO) and the Unviversity of Ottawa Heart Institute (UOHI)

Comments are closed.

%d bloggers like this: